Naproxen/esomeprazole magnesium

From Wikipedia, the free encyclopedia
  (Redirected from Vimovo)
Jump to navigation Jump to search
Naproxen/esomeprazole magnesium
Combination of
Esomeprazole magnesiumproton pump inhibitor
Clinical data
Trade namesVimovo
Legal status
Legal status

Naproxen/esomeprazole magnesium (Vimovo) is a pain reliever in the form of a tablet for oral consumption, with delayed release of esomeprazole magnesium, "a stomach acid–reducing proton pump inhibitor (PPI)"[1] and naproxen, produced by AstraZeneca.[2] Vimovo is FDA approved for use for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[3] It is intended to decrease the risk of gastric ulcers from treatment with nonsteroidal anti-inflammatory drugs.[3]

Horizon Pharma[edit]

Vimoco was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to VIMOVO".[1]

In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo.[4] According to The Atlantic, "since 2014, Horizon Pharma’s net sales have been more than $455 million".[4]


  1. ^ a b "Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance". Horizon Pharma, Inc. Deerfield, Illinois. November 19, 2013.(NASDAQ: HZNP)
  2. ^ "Vimovo-Astrazeneca".
  3. ^ a b "VIMOVO® (naproxen and esomeprazole magnesium) Tablets". Horizon Pharma. nd. Retrieved June 20, 2017.
  4. ^ a b Allen, Marshall (June 20, 2017). "How Two Common Medications Became One $455 Million Specialty Pill". The Atlantic. Retrieved June 20, 2017. After I was prescribed a brand-name drug I didn’t need and given a coupon to cover the out-of-pocket costs, I discovered yet another reason why Americans pay too much for health care.